Determinants of survival in progressive multifocal leukoencephalopathy
- 10 November 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 73 (19), 1551-1558
- https://doi.org/10.1212/wnl.0b013e3181c0d4a1
Abstract
We sought to characterize the role of immunologic, virologic, and radiologic determinants of survival in patients with progressive multifocal leukoencephalopathy (PML). We recorded the clinical outcome of 60 patients with PML (73% HIV+) who were prospectively evaluated between 2000 and 2007 for the presence of JC virus (JCV)-specific CD8+ cytotoxic T-lymphocytes (CTL) in blood. Estimated probability of survival at 1 year was 52% for HIV+/PML and 58% for HIV- patients with PML. Patients with PML with detectable CTL within 3 months of diagnosis had a 1-year estimated survival of 73% compared to 46% for those without CTL (hazard ratio [HR] for death = 0.47, 95% confidence interval [CI] 0.13-1.75, p = 0.26). Patients with CTL response had an increased likelihood of having contrast enhancement of PML lesions and immune reconstitution inflammatory syndrome (odds ratio 3.7 and 7.8). Estimated 1-year survival was 48% in HIV+ patients with PML with CD4 count 200/microL (HR for death 1.41, 95% CI 0.27-7.38, p = 0.68). JCV DNA was detected in the urine of 48% and in the blood of 56% of patients with PML, but viruria and viremia were not associated with survival. The presence of JC virus (JCV)-specific cytotoxic T-lymphocytes (CTL) was associated with a trend toward longer survival in patients with progressive multifocal leukoencephalopathy (PML), which was more pronounced than the impact of CD4 count in HIV+ patients with PML early after diagnosis. Despite the association of contrast enhancement and immune reconstitution inflammatory syndrome with JCV-specific CTL, these cannot be considered as surrogate markers for the prognostic value of the CTL. Strategies aiming at improving the cellular immune response may improve the course of PML.Keywords
This publication has 23 references indexed in Scilit:
- PML-IRIS in patients with HIV infectionNeurology, 2009
- Steroids for PML-IRISNeurology, 2009
- Efficient in vitro expansion of JC virus-specific CD8+ T-cell responses by JCV peptide-stimulated dendritic cells from patients with progressive multifocal leukoencephalopathyVirology, 2009
- Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysisAIDS, 2008
- Mirtazapine in Progressive Multifocal Leukoencephalopathy Associated with Polycythemia VeraThe Journal of Infectious Diseases, 2007
- Frequency and Phenotype of JC Virus-Specific CD8+T Lymphocytes in the Peripheral Blood of Patients with Progressive Multifocal LeukoencephalopathyJournal of Virology, 2007
- Progressive Multifocal Leukoencephalopathy as a Complication of Hepatitis C Virus Treatment in an HIV-Negative PatientClinical Infectious Diseases, 2005
- Clinical Course and Prognostic Factors of Progressive Multifocal Leukoencephalopathy in Patients Treated with Highly Active Antiretroviral TherapyClinical Infectious Diseases, 2003
- Progressive Multifocal Leukoencephalopathy: Improved Survival of Human Immunodeficiency Virus–infected Patients in the Protease Inhibitor EraThe Journal of Infectious Diseases, 1999
- Predictive factors for prolonged survival in acquired immunodeficiency syndrome—associated progressive multifocal leukoencephalopathyAnnals of Neurology, 1998